XT
ACHL

XTX Topco’s Achilles Therapeutics ACHL Stock Holding History

XTX Topco’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-38,923
Closed -$57.6K – 3396
2025
Q1 		$57.6K Buy
38,923
+12,099
+45% +$15.7K ﹤0.01% 1978
2024
Q4 		$30.6K Buy
+26,824
New +$27.6K ﹤0.01% 1975
2024
Q3 		– Sell
-51,660
Closed -$42.1K – 2720
2024
Q2 		$42.1K Buy
51,660
+36,441
+239% +$32K ﹤0.01% 1527
2024
Q1 		$19K Buy
+15,219
New +$16.4K ﹤0.01% 1614
2023
Q4 		– Sell
-21,084
Closed -$19.2K – 2253
2023
Q3 		$19.2K Buy
+21,084
New +$20.1K ﹤0.01% 1380

Other funds holding ACHL

RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

XTX Topco's ACHL Position: Q2 2025 in Review

XTX Topco sold out of Achilles Therapeutics (ACHL) in Q2 2025, closing a stake of 38,923 shares — an estimated $57.6K sold.

XTX Topco first reported a position in ACHL in Q3 2023 and held it in 5 quarters. The position peaked at $57.6K in Q1 2025. 2 funds tracked by Wall St. Rank hold ACHL as of Q2 2025.

  • XTX Topco reported no remaining Achilles Therapeutics position as of Q2 2025 after selling out during the quarter.
  • XTX Topco sold 38,923 Achilles Therapeutics shares in Q2 2025, an estimated $57.6K.
  • XTX Topco first reported a position in Achilles Therapeutics in Q3 2023 and held it in 5 quarters.
  • XTX Topco's Achilles Therapeutics position peaked at $57.6K in Q1 2025.
  • 2 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q2 2025.

Based on XTX Topco's 13F filing for Q2 2025, filed 12 Aug 2025.